Hemab Collects $157M to Target 'Underserved' Blood Diseases
Hemab, a startup with medicines in testing and development, aims to build the "ultimate coagulation disorders company," according to its CEO.
Innovation in hemophilia has improved over the last decade with longer-lasting therapies, antibody drugs, and gene therapies. However, progress in other bleeding diseases, such as Glanzmann thrombasthenia, Von Willebrand, and Factor VII deficiency, has been slower.
questions about market size have left drugmakers with "less commercial incentive" to develop treatments
These disorders require complex innovations and bioengineering to develop better options, which may be changing with Hemab's efforts.
Author's summary: Hemab raises $157M to tackle underserved blood diseases.
- Glanzmann thrombasthenia
- Von Willebrand
- Factor VII deficiency
More News
- Why hasn’t Zohran Mamdani taken a position on the ballot proposals?
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Horse grazing in The Villages - Villages-News.com
- Exploring the Flawlessness of Nature - Blood: River of Red Gold
- First Duel Night Abyss Figure Is Based on Psyche
- Global PAH data shows rising cases and risk factors in elderly
- SJHN Daily: Celebrini Named NHL First Star of the Week
- MCU: Jeremy Allen White Responds to Popular X-Men Fan Casting
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- Johnson’s “Protecting Chicago” budget proposes nearly $500M in tax hikes